PURPOSE: This trial was undertaken (1) to determine the feasibility of enrolling asymptomatic ovarian cancer patients with CA-125 elevation in a trial with the protein kinase C iota (PKCι) inhibitor auranofin and (2) to understand patients' perceptions of CA-125 monitoring. METHODS: Asymptomatic ovarian cancer patients with CA-125 elevation received 3 mg auranofin orally twice per day and were evaluated. The patients participated in interviews about CA-125 monitoring. RESULTS: Ten patients were enrolled in slightly over 6 months, exceeding our anticipated accrual rate. Four manifested stable CA-125 levels for 1 month or longer. The median progression-free survival was 2.8 months (95% CI: 1.3-3.8); auranofin was well tolerated. One patient had baseline and monthly CA-125 levels of 5,570, 6,085, 3,511, and 2,230 U/ml, respectively, stopped auranofin because of radiographic progression at 3 months, and manifested an increase in CA-125 to 7,168 U/ml approximately 3 months later. Patient interviews revealed (1) the important role of CA-125 in cancer monitoring, (2) ardent advocacy of CA-125 testing, and (3) an evolution toward CA-125 assuming a life of its own. CONCLUSIONS: This study showed the feasibility of enrolling asymptomatic ovarian cancer patients with CA-125 elevation in a trial with auranofin. One patient had a decline in CA-125, suggesting that PKCι inhibition merits further study in ovarian cancer.
PURPOSE: This trial was undertaken (1) to determine the feasibility of enrolling asymptomatic ovarian cancerpatients with CA-125 elevation in a trial with the protein kinase C iota (PKCι) inhibitor auranofin and (2) to understand patients' perceptions of CA-125 monitoring. METHODS: Asymptomatic ovarian cancerpatients with CA-125 elevation received 3 mg auranofin orally twice per day and were evaluated. The patients participated in interviews about CA-125 monitoring. RESULTS: Ten patients were enrolled in slightly over 6 months, exceeding our anticipated accrual rate. Four manifested stable CA-125 levels for 1 month or longer. The median progression-free survival was 2.8 months (95% CI: 1.3-3.8); auranofin was well tolerated. One patient had baseline and monthly CA-125 levels of 5,570, 6,085, 3,511, and 2,230 U/ml, respectively, stopped auranofin because of radiographic progression at 3 months, and manifested an increase in CA-125to 7,168 U/ml approximately 3 months later. Patient interviews revealed (1) the important role of CA-125 in cancer monitoring, (2) ardent advocacy of CA-125 testing, and (3) an evolution toward CA-125 assuming a life of its own. CONCLUSIONS: This study showed the feasibility of enrolling asymptomatic ovarian cancerpatients with CA-125 elevation in a trial with auranofin. One patient had a decline in CA-125, suggesting that PKCι inhibition merits further study in ovarian cancer.
Authors: Gordon J S Rustin; Maria E L van der Burg; Clare L Griffin; David Guthrie; Alan Lamont; Gordon C Jayson; Gunnar Kristensen; César Mediola; Corneel Coens; Wendi Qian; Mahesh K B Parmar; Ann Marie Swart Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: Jean A Hurteau; Mark F Brady; Kathleen M Darcy; William P McGuire; Pamela Edmonds; Michael L Pearl; Iouri Ivanov; Krishnansu S Tewari; Robert S Mannel; Kristine Zanotti; Doris M Benbrook Journal: Gynecol Oncol Date: 2010-09-17 Impact factor: 5.482
Authors: Lin Zhang; Jia Huang; Nuo Yang; Shun Liang; Andrea Barchetti; Antonis Giannakakis; Mark G Cadungog; Ann O'Brien-Jenkins; Marco Massobrio; Katherine F Roby; Dionyssios Katsaros; Phyllis Gimotty; Ralf Butzow; Barbara L Weber; George Coukos Journal: Cancer Res Date: 2006-05-01 Impact factor: 12.701
Authors: Aaron S Mansfield; Alan P Fields; Aminah Jatoi; Yingwei Qi; Alex A Adjei; Charles Erlichman; Julian R Molina Journal: Anticancer Drugs Date: 2013-11 Impact factor: 2.248
Authors: James D Harrison; Ilona Juraskova; Caroline Anderson; Kathryn Nattress; Philip Beale; Anna-Lena Lopez; Jonathan Carter Journal: Int J Gynecol Cancer Date: 2009-08 Impact factor: 3.437
Authors: Ziyan Y Pessetto; Bin Chen; Hani Alturkmani; Stephen Hyter; Colleen A Flynn; Michael Baltezor; Yan Ma; Howard G Rosenthal; Kathleen A Neville; Scott J Weir; Atul J Butte; Andrew K Godwin Journal: Oncotarget Date: 2017-01-17
Authors: Stephen Hyter; Jeff Hirst; Harsh Pathak; Ziyan Y Pessetto; Devin C Koestler; Rama Raghavan; Dong Pei; Andrew K Godwin Journal: Oncotarget Date: 2017-12-26
Authors: Lauren Fernandez-Vega; Valeria A Ruiz Silva; Tania M Domínguez-González; Sebastián Claudio-Betancourt; Rafael E Toro-Maldonado; Luisa C Capre Maso; Karina Sanabria Ortiz; Jean A Pérez-Verdejo; Janeishly Román González; Grecia T Rosado-Fraticelli; Fabiola Pagán Meléndez; Fabiola M Betancourt Santiago; Daniel A Rivera-Rivera; Carlos Martínez Navarro; Andrea C Bruno Chardón; Axel O Vera; Arthur D Tinoco Journal: Inorganics (Basel) Date: 2020-01-26